260 related articles for article (PubMed ID: 15552597)
41. Skin-lightening effects of a new face care product in patients with melasma.
Scherdin U; Bürger A; Bielfeldt S; Filbry A; Weber T; Schölermann A; Wigger-Alberti W; Rippke F; Wilhelm KP
J Cosmet Dermatol; 2008 Mar; 7(1):68-75. PubMed ID: 18254815
[TBL] [Abstract][Full Text] [Related]
42. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore.
Goh CL; Dlova CN
Singapore Med J; 1999 Jul; 40(7):455-8. PubMed ID: 10560271
[TBL] [Abstract][Full Text] [Related]
43. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity.
Arellano I; Cestari T; Ocampo-Candiani J; Azulay-Abulafia L; Bezerra Trindade Neto P; Hexsel D; Machado-Pinto J; Muñoz H; Rivitti-Machado MC; Sittart JA; Trindade de Almeida AR; Rego V; Paliargues F; Marques-Hassun K
J Eur Acad Dermatol Venereol; 2012 May; 26(5):611-8. PubMed ID: 21623930
[TBL] [Abstract][Full Text] [Related]
44. Glycolic acid peels versus amino fruit acid peels in the treatment of melasma.
Ilknur T; Biçak MU; Demirtaşoğlu M; Ozkan S
Dermatol Surg; 2010 Apr; 36(4):490-5. PubMed ID: 20187899
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment of hydroquinone-resistant melasma using topical methimazole.
Malek J; Chedraoui A; Nikolic D; Barouti N; Ghosn S; Abbas O
Dermatol Ther; 2013; 26(1):69-72. PubMed ID: 23384022
[TBL] [Abstract][Full Text] [Related]
46. Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial.
Padhi T; Pradhan S
Indian J Dermatol; 2015; 60(5):520. PubMed ID: 26538719
[TBL] [Abstract][Full Text] [Related]
47. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
Ferreira Cestari T; Hassun K; Sittart A; de Lourdes Viegas M
J Cosmet Dermatol; 2007 Mar; 6(1):36-9. PubMed ID: 17348994
[TBL] [Abstract][Full Text] [Related]
48. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma.
Torok HM; Jones T; Rich P; Smith S; Tschen E
Cutis; 2005 Jan; 75(1):57-62. PubMed ID: 15732437
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic Insights in Melasma and Hyperpigmentation Management.
Huerth KA; Hassan S; Callender VD
J Drugs Dermatol; 2019 Aug; 18(8):718-729. PubMed ID: 31424704
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma.
Cestari T; Adjadj L; Hux M; Shimizu MR; Rives VP
J Drugs Dermatol; 2007 Feb; 6(2):153-60. PubMed ID: 17373174
[TBL] [Abstract][Full Text] [Related]
51. Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study.
Wind BS; Kroon MW; Meesters AA; Beek JF; van der Veen JP; Nieuweboer-Krobotová L; Bos JD; Wolkerstorfer A
Lasers Surg Med; 2010 Sep; 42(7):607-12. PubMed ID: 20806385
[TBL] [Abstract][Full Text] [Related]
52. Improved quality of life with effective treatment of facial melasma: the pigment trial.
Balkrishnan R; Kelly AP; McMichael A; Torok H
J Drugs Dermatol; 2004; 3(4):377-81. PubMed ID: 15303781
[TBL] [Abstract][Full Text] [Related]
53. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study.
Trelles MA; Velez M; Gold MH
J Drugs Dermatol; 2010 Apr; 9(4):315-22. PubMed ID: 20514787
[TBL] [Abstract][Full Text] [Related]
54. Hyperpigmentation and melasma.
Rigopoulos D; Gregoriou S; Katsambas A
J Cosmet Dermatol; 2007 Sep; 6(3):195-202. PubMed ID: 17760699
[TBL] [Abstract][Full Text] [Related]
55. Systematic review of randomized controlled trials on interventions for melasma: an abridged Cochrane review.
Jutley GS; Rajaratnam R; Halpern J; Salim A; Emmett C
J Am Acad Dermatol; 2014 Feb; 70(2):369-73. PubMed ID: 24438951
[TBL] [Abstract][Full Text] [Related]
56. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study.
Kroon MW; Wind BS; Beek JF; van der Veen JP; Nieuweboer-Krobotová L; Bos JD; Wolkerstorfer A
J Am Acad Dermatol; 2011 Mar; 64(3):516-23. PubMed ID: 21255869
[TBL] [Abstract][Full Text] [Related]
57. Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel.
Berardesca E; Cameli N; Primavera G; Carrera M
Dermatol Surg; 2006 Apr; 32(4):526-31. PubMed ID: 16681660
[TBL] [Abstract][Full Text] [Related]
58. Melasma: a comprehensive update: part II.
Sheth VM; Pandya AG
J Am Acad Dermatol; 2011 Oct; 65(4):699-714. PubMed ID: 21920242
[TBL] [Abstract][Full Text] [Related]
59. Melasma: clinical diagnosis and management options.
Rodrigues M; Pandya AG
Australas J Dermatol; 2015 Aug; 56(3):151-63. PubMed ID: 25754098
[TBL] [Abstract][Full Text] [Related]
60. Combination therapy with salicylic acid chemical peels, glycyrrhizin compound, and vitamin C for Riehl's melanosis.
Wang L; Wen X; Hao D; Li Y; Du D; Jiang X
J Cosmet Dermatol; 2020 Jun; 19(6):1377-1380. PubMed ID: 31524950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
